Fewer Side Effects Many people stop GLP-1s early due to nausea, reflux, constipation, or fatigue
But now to extend this to people who are not such high risk, but these large trials, we keep learning more
GLP-1 agonists, which primarily target extrahepatic mechanisms to ameliorate metabolic disorders, when used in conjunction with resmetirom, focusing on intrahepatic mechanisms, offer a complementary approach in the management of MASH and liver fibrosis
If you are in this phase, the most important thing to understand is that each hair falling out is making room for a new hair
For example, Rybelsus (semaglutide tablets), the first oral GLP-1 approved for type 2 diabetes, has demonstrated meaningful weight loss in clinical studies, although it currently requires strict administration guidelines (empty stomach, limited fluid intake before and after dosing)